Revenue surged by 41.8% year-on-year to ₹4,197 crore, compared to ₹2,959 crore. EBITDA experienced a 40.7% increase to ₹1,356 crore from ₹964 crore, with the EBITDA margin at 32%, slightly down from 33% the previous year.
The company’s revenues from India amounted to ₹2,215 crore, reflecting a 43% growth, with base business growth at 15%, surpassing the IPM growth of 10%, according to AIOCD PharmaTrac data.
Also Read: Torrent Pharma Q2 Results: Profit up 30% YoY; US, India growth lift revenue 14%
For FY26, revenues from India reached ₹7,645 crore, a 20% increase, highlighting that its base business is among the fastest-growing in the top 10 pharmaceutical companies. The launch of Gx Semaglutide has also been promising, capturing 38% of the market share (combined for oral and injectable) based on April 26 PharmaTrac data.
In Brazil, revenues grew by 30% to ₹455 crore, while constant currency revenue rose 11% to R$ 259 million. According to IQVIA, Torrent experienced a 17% growth against the market’s 6%, driven by successful brand performance and recent product launches. The company has 58 products undergoing ANVISA review. For FY26, revenues from Brazil totaled ₹1,362 crore, a 24% rise, with constant currency revenue of R$ 823 million, up 12%.
Also Read: Torrent Pharma’s Gujarat oncology plant inspection by USFDA concludes with zero observations
In the United States, revenues climbed 31% to ₹396 crore, with base business revenue increasing by 16% and constant currency revenue reaching $38 million, up 9%. For FY26, US revenues were ₹1,363 crore, a 24% growth, while base business expanded by 20% due to new launches, with constant currency revenue at $149 million, up 14%.
Germany reported a revenue increase of 16% to ₹333 crore, but constant currency revenue declined 1% to €31 million, attributed to supply disruptions from a third-party supplier. For FY26, revenues in Germany were ₹1,249 crore, up 10%, while constant currency revenue decreased by 3% to €122 million.
The company has proposed to seek approval from shareholders to raise up to ₹5,000 crore through the issuance of equity shares, including convertible bonds or debentures, via Qualified Institutional Placement (QIP) and/or other permitted methods at its upcoming Annual General Meeting.
Also Read: Torrent Pharma Q3 net profit surges 26% on strong revenue growth, declares ₹29 dividend
It has also suggested a final dividend of ₹9 per equity share of face value ₹5, equating to 180%, for FY26. If shareholder approval is granted, the dividend is projected to be paid or dispatched around June 25, 2026.
Previously, Torrent Pharmaceuticals issued an interim dividend of ₹29 per equity share, amounting to 580%, in the last quarter.
Shares of Torrent Pharmaceuticals Ltd closed at ₹4,494.00, rising by ₹23.15, or 0.52%, on the BSE.
